ArticleNature genetics2018
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
Abstract read
In one paragraph
Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it.
- In vitro assays as a tool to personalize treatment in central nervous system tumors: a systematic literature review.Clinical and experimental medicine · 2026Pooled it
- Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.Genome medicine · 2021Trial
- Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study.Targeted oncology · 2020Trial
- Construction Strategies, Microenvironmental Modelling and Precision-Therapy Applications of Glioma Organoid Models.Cancers · 2026Review
- Attract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas.Neuro-oncology · 2026Review
- [Standardized Construction of Lung Cancer Organoids and Their Application Progress in the Precise Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- A 3D Bioprinted Platform That Maintains the Functional Integrity of Primary AML Cells.Cell proliferation · 2026Article
- Core transcriptional regulatory circuitry identified from patient-derived tumor cells provides a specific vulnerability for rhabdomyosarcoma.Cell death & disease · 2026Article
- Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma.International journal of molecular sciences · 2026Article
- Foundation models and deep learning for cancer drug response prediction: a framework for data, metrics, and validation.Briefings in bioinformatics · 2026Review
- Predicting therapeutic responses in metastatic colorectal cancer through personalized functional profiling of patient-derived spheroids.NPJ precision oncology · 2026Article
- A Pan-Cancer Ex Vivo Drug Screen Atlas for Functional Precision Oncology.bioRxiv : the preprint server for biology · 2026Article
- Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.NPJ precision oncology · 2026Article
- Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations.Nature communications · 2026Article
- High-throughput 3D engineered paediatric tumour models for precision medicine.Molecular systems biology · 2025Article
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- Adapting systems biology to address the complexity of human disease in the single-cell era.Nature reviews. Genetics · 2025Review
- Establishment of a patient-derived drug-resistant oral squamous cell carcinoma animal model.Animal models and experimental medicine · 2025Article
- Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones.Experimental & molecular medicine · 2025Article
- MRAS: Master Regulator Analysis of Alternative Splicing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
54 authors.
Jin-Ku LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-0263-3234
Zhaoqi LiuDepartment of Systems Biology, Columbia University, New York, NY, USA.
Jason K SaInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Sang ShinInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Jiguang WangDivision of Life Science, Hong Kong University of Science and Technology, Hong Kong, China.ORCID http://orcid.org/0000-0002-6923-4097
Mykola BordyuhDepartment of Systems Biology, Columbia University, New York, NY, USA.
Hee Jin ChoInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Oliver ElliottDepartment of Systems Biology, Columbia University, New York, NY, USA.
Timothy ChuDepartment of Systems Biology, Columbia University, New York, NY, USA.
Seung Won ChoiInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-1203-6126
Daniel I S RosenbloomDepartment of Systems Biology, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1413-3907
In-Hee LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-8857-1355
Yong Jae ShinInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Hyun Ju KangInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Donggeon KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Sun Young KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Moon-Hee SimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jusun KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Taehyang LeeDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Yun Jee SeoInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Hyemi ShinInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Mijeong LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Sung Heon KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Yong-Jun KwonInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Jeong-Woo OhInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Minsuk SongInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Misuk KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
Doo-Sik KongDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jung Won ChoiDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ho Jun SeolDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jung-Il LeeDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Seung Tae KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Joon Oh ParkDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
Kyoung-Mee KimDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sang-Yong SongDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jeong-Won LeeDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Hee-Cheol KimDeparment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jeong Eon LeeDeparment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Min Gew ChoiDeparment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sung Wook SeoDepartment of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Young Mog ShimDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jae Ill ZoDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Byong Chang JeongDeparment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Yeup YoonResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Gyu Ha RyuResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Nayoung K D KimResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-8350-6266
Joon Seol BaeResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Woong-Yang ParkResearch Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Jeongwu LeeDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Roel G W VerhaakThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0003-2773-0436
Antonio IavaroneInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Jeeyun LeeDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea. jyunlee@skku.edu.ORCID http://orcid.org/0000-0002-4911-6165
Raul RabadanDepartment of Systems Biology, Columbia University, New York, NY, USA. rr2579@cumc.columbia.edu.
Do-Hyun NamInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea. nsnam@skku.edu.
Funding
Topology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4MIdentification and modeling of driver genetic modules in glioblastomaR01CA179044 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2014 to 2018
$2.3M(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic DataR01CA185486 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LASORELLA, ANNA, RABADAN, RAUL · 2014 to 2017
$2.1MNCI NIH HHS R01 CA179044NCI NIH HHS R01 CA185486NCI NIH HHS U54 CA193313
Abstract
Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors to guide optimal patient-tailored therapy. Towards this goal, we have established a compilation of pharmacological landscapes of 462 patient-derived tumor cells (PDCs) across 14 cancer types, together with genomic and transcriptomic profiling in 385 of these tumors. Compared with the traditional long-term cultured cancer cell line models, PDCs recapitulate the molecular properties and biology of the diseases more precisely. Here, we provide insights into dynamic pharmacogenomic associations, including molecular determinants that elicit therapeutic resistance to EGFR inhibitors, and the potential repurposing of ibrutinib (currently used in hematological malignancies) for EGFR-specific therapy in gliomas. Lastly, we present a potential implementation of PDC-derived drug sensitivities for the prediction of clinical response to targeted therapeutics using retrospective clinical studies.
Indexed as
Molecular Targeted TherapyAntineoplastic AgentsBiomarkers, PharmacologicalBiomarkers, TumorCell LineageDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFeasibility StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHEK293 CellsHumansMedical OncologyNeoplasmsPanobinostatPatient-Centered CareAntineoplastic AgentsBiomarkers, PharmacologicalBiomarkers, TumorPanobinostat
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.